Products
Explore our advanced sequencing products for turning complex molecular signals into high-confidence readouts across clinical testing, RNA quality control, and translational methylation programs.


Chinook
Long-read pharmacogenomics uses long DNA sequencing reads to genotype pharmacogenes with variants phased directly from the reads. Short-read and SNP array tests often infer phase and can miss repeats, rare variants, and copy-number changes. Long reads measure these features directly, producing diplotypes and structural context from a single targeted assay.
CYP2D6 can be deleted, duplicated, or fused with the neighboring CYP2D7 pseudogene to form hybrid alleles, structures that short reads often cannot distinguish. Long reads capture these structures in the same data used for small-variant calling. Chinook-based analysis then reports CYP2D6 star alleles with copy number and hybrid structure, such as *1/*4×2 or *36+*10.
Phasing shows whether two variants sit on the same copy of a gene or on different copies, which can change the assigned diplotype and predicted metabolizer phenotype. For DPYD, this matters when a sample carries more than one variant. For UGT1A1, long reads size the *28 promoter TA repeat directly, alongside nearby variants on the same haplotype.
The panel covers 49 pharmacogenes plus mitochondrial DNA: 39 genes sequenced full-length and 10 targeted at key PGx variants. Genes include CYP2D6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, DPYD, UGT1A1, TPMT, NUDT15, SLCO1B1, VKORC1, G6PD, HLA-A, and HLA-B. The complete gene list is available in the case study.
Renew accepts human genomic DNA and whole blood collected in a standard EDTA tube. We also work with banked samples from completed or ongoing studies, and our team reviews archived DNA quality before sequencing. Questions about sample preparation or shipping can be directed to info@renewbt.com.
Typical turnaround is 14-21 days from sample receipt to data delivery. Timelines depend on sample count, sample quality, and analysis scope, and are confirmed during project setup. Live project status is available through the customer portal.
Yes, for exploratory analyses. Long-Read PGx supports research use and fit-for-purpose studies, such as PGx covariates in safety, PK, and PK/PD analyses, in prospective and retrospective designs. For programs with an intended clinical use, Renew offers assay validation pathways through our CAP/CLIA-certified laboratory.
Yes. Genes can be added or prioritized based on your program's compounds and metabolic pathways. Renew's Targeted Panel Development team supports custom capture design and validation.
Each project includes a QC report, aligned reads (BAM), phased variant calls (VCF), and a PGx report with PharmCAT diplotypes and Chinook CYP2D6 structures. Reporting formats can be adapted for sponsor and CRO data systems, with delivery through the customer portal or AWS S3.